SecBot SecBot
SECBOTREPLAY Home › Report › ZYME

ZYME · Zymeworks secured $250 million in non-dilutive financing from Royalty…

Zymeworks Inc. · PRESS-RELEASE filed Mar 2, 2026 at 06:01 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Mar 2, 2026 at 06:01 ET

Zymeworks secured $250 million in non-dilutive financing from Royalty Pharma through a royalty-backed note, funded by 30% of future worldwide royalties on Ziihera sales. The deal extends Zymeworks' cash runway beyond 2028 and supports share repurchases and potential acquisitions, while the company retains 70% of royalties and all milestone payments.

  • Zymeworks to receive $250 million from Royalty Pharma via a non-recourse, royalty-backed note
  • Repayment sourced from 30% of global tiered royalties on Ziihera sales; Zymeworks retains 70%
  • Royalty Pharma's cumulative repayment capped at 1.65x by 2033 or 1.925x thereafter (~$412.5M max)
  • Proceeds to fund stock repurchases, potential acquisitions, and extend cash runway beyond 2028

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access